scholarly journals Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.

Circulation ◽  
1993 ◽  
Vol 87 (2) ◽  
pp. 659-675 ◽  
Author(s):  
V Fuster ◽  
M L Dyken ◽  
P S Vokonas ◽  
C Hennekens
Keyword(s):  
Cardiovascular Disease ◽  
Therapeutic Agent ◽  
Writing Group

scholarly journals Emerging Roles of Propolis: Antioxidant, Cardioprotective, and Antiangiogenic Actions

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Julio Beltrame Daleprane ◽  
Dulcinéia Saes Abdalla
Keyword(s):  
Cardiovascular Disease ◽  
Therapeutic Agent ◽  
Cellular Signaling ◽  
Degenerative Diseases ◽  
Active Components ◽  
Beneficial Effects ◽  
Genomic Level ◽  
Anti Inflammatory ◽  
Biological Actions

Propolis has attracted attention in recent years due to its beneficial effects, which make it a potential preventive and therapeutic agent as well as a useful additive in food and cosmetics. The aim of this review is to discuss the growing evidence that propolis may, via a diverse array of biological actions, assist in the prevention of some inflammation-mediated pathologies including cardiovascular disease. The active components of propolis that have been identified so far include polyphenols and flavonoids. These compounds have cardioprotective, vasoprotective, antioxidant, antiatherosclerotic, anti-inflammatory and antiangiogenic actions. Many studies have been undertaken to elucidate the mechanism(s) by which propolis acts, which involve cellular signaling targets and interactions at the genomic level. This review will highlight the effects of propolis that may assist in the prevention of chronic degenerative diseases, such as cardiovascular disease.

scholarly journals Astaxanthin: A Potential Therapeutic Agent in Cardiovascular Disease

Marine Drugs ◽  
2011 ◽  
Vol 9 (3) ◽  
pp. 447-465 ◽  
Author(s):  
Robert G. Fassett ◽  
Jeff S. Coombes
Keyword(s):  
Cardiovascular Disease ◽  
Therapeutic Agent ◽  
Potential Therapeutic Agent

Aspirin as a Therapeutic Agent in Cardiovascular Disease

Circulation ◽  
1997 ◽  
Vol 96 (8) ◽  
pp. 2751-2753 ◽  
Author(s):  
Charles H. Hennekens ◽  
Mark L. Dyken ◽  
Valentin Fuster
Keyword(s):  
Cardiovascular Disease ◽  
Therapeutic Agent

ACE2 as therapeutic agent

2020 ◽  
Vol 134 (19) ◽  
pp. 2581-2595
Author(s):  
Qiuhong Li ◽  
Maria B. Grant ◽  
Elaine M. Richards ◽  
Mohan K. Raizada
Keyword(s):  
Therapeutic Agent ◽  
Renin Angiotensin System ◽  
Peptide Hormone ◽  
Experimental Models ◽  
Electrolyte Balance ◽  
Ang Ii ◽  
Angiotensin Converting Enzyme 2 ◽  
Beneficial Effects ◽  
Overwhelming Evidence ◽  
Future Challenges

Abstract The angiotensin-converting enzyme 2 (ACE2) has emerged as a critical regulator of the renin–angiotensin system (RAS), which plays important roles in cardiovascular homeostasis by regulating vascular tone, fluid and electrolyte balance. ACE2 functions as a carboxymonopeptidase hydrolyzing the cleavage of a single C-terminal residue from Angiotensin-II (Ang-II), the key peptide hormone of RAS, to form Angiotensin-(1-7) (Ang-(1-7)), which binds to the G-protein–coupled Mas receptor and activates signaling pathways that counteract the pathways activated by Ang-II. ACE2 is expressed in a variety of tissues and overwhelming evidence substantiates the beneficial effects of enhancing ACE2/Ang-(1-7)/Mas axis under many pathological conditions in these tissues in experimental models. This review will provide a succinct overview on current strategies to enhance ACE2 as therapeutic agent, and discuss limitations and future challenges. ACE2 also has other functions, such as acting as a co-factor for amino acid transport and being exploited by the severe acute respiratory syndrome coronaviruses (SARS-CoVs) as cellular entry receptor, the implications of these functions in development of ACE2-based therapeutics will also be discussed.

Sign in / Sign up

Export Citation Format

Share Document